EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (Tarceva) yield modest increases in survival when administered to NSCLC patients following chemotherapy.